当前位置: X-MOL 学术Microb. Pathog. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Enhancing immune responses by a novel multi-epitope ROP8 DNA vaccine plus interleukin-12 plasmid as a genetic adjuvant against acute Toxoplasma gondii infection in BALB/c mice.
Microbial Pathogenesis ( IF 3.8 ) Pub Date : 2020-08-05 , DOI: 10.1016/j.micpath.2020.104435
Masoud Foroutan 1 , Mohammad Barati 1 , Fatemeh Ghaffarifar 2
Affiliation  

Background

Toxoplasmosis is a widespread zoonotic infection, caused by an obligate intracellular protozoan. The infection is often asymptomatic in immunocompetent individuals, although in persons with impaired immune system may lead to severe and progressive complications. Constant attempts of scientists have made valuable findings in the development of Toxoplasma gondii (T. gondii) candidate vaccines. However, an effective vaccine has not been successfully developed yet. In the current study, we tested the co-delivery of a novel multi-epitope pcROP8 DNA vaccine with a plasmid encoding IL-12 (pcIL-12) to assess the immune responses in BALB/c mice against acute T. gondii infection.

Methods

BALB/c mice were immunized on days 0, 21, and 42. The immune responses of both vaccinated and control groups were evaluated using cytokine and antibody measurements, lymphocyte proliferation assay, and survival time.

Results

The findings demonstrated that immunization with multi-epitope pcROP8 significantly enhanced the level of anti-T. gondii antibodies, TH1-type cellular immune responses, lymphocyte proliferation, and prolonged survival time, compared to control groups (P < 0.05). Furthermore, the use of pcIL-12 as a genetic adjuvant led to enhancements of the above-mentioned immune responses in BALB/c mice (P < 0.05).

Conclusions

The co-administration of pcIL-12 with multi-epitope pcROP8 vaccine, could successfully enhance the level of protection. Thus, this immunization regimen may represent an effective vaccine strategy against acute T. gondii infection.



中文翻译:

通过新型多表位ROP8 DNA疫苗和白介素12质粒增强免疫应答,作为抗BALB / c小鼠急性弓形虫感染的遗传佐剂。

背景

弓形虫病是一种广泛的人畜共患病感染,由专一的细胞内原生动物引起。免疫能力强的人通常无症状,尽管免疫系统受损的人可能会导致严重和进行性并发症。科学家的不断努力在弓形虫T. gondii)候选疫苗的开发中取得了宝贵的发现。但是,尚未成功开发出有效的疫苗。在当前的研究中,我们测试了新型多表位pcROP8 DNA疫苗与编码IL-12(pcIL-12)的质粒的共同递送,以评估BALB / c小鼠对弓形虫的免疫反应。

方法

在第0、21和42天对BALB / c小鼠进行了免疫。使用细胞因子和抗体测量,淋巴细胞增殖测定以及存活时间评估了接种组和对照组的免疫反应。

结果

研究结果表明,与对照组相比,多表位pcROP8的免疫显着提高了抗弓形虫抗体的水平,TH1型细胞免疫应答,淋巴细胞增殖和延长了生存时间(P  <0.05)。此外,使用pcIL-12作为遗传佐剂可增强BALB / c小鼠的上述免疫应答(P  <0.05)。

结论

pcIL-12与多表位pcROP8疫苗的共同给药可成功提高保护水平。因此,该免疫方案可以代表针对急性弓形虫感染的有效疫苗策略。

更新日期:2020-08-05
down
wechat
bug